Liver metastases from melanoma: Hepatic intra-arterial chemotherapy. a retrospective study

Journal of Chemotherapy

Volumn 23, Issue 5, 2011, Pages 300-305

  Farolfi, A ^a   Ridolfi, L ^a   Guidoboni, M ^a   Milandri, C ^a   Calzolari, F ^b   Scarpi, E ^c   Amadori, D ^a   Ridolfi, R ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c Data Management Unit   (Italy)

Author keywords

Carboplatin; Fotemustine; Hepatic intra arterial chemotherapy; Metastatic melanoma; Treatment related adverse events; Uveal melanoma

Indexed keywords

CARBOPLATIN; FOTEMUSTINE; ANTINEOPLASTIC AGENT; NITROSOUREA DERIVATIVE; ORGANOPHOSPHORUS COMPOUND;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CATHETER COMPLICATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DRUG TOLERABILITY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HYPERTRANSAMINASEMIA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; UVEA MELANOMA; VOMITING; DRUG DELIVERY SYSTEM; DRUG MONITORING; ELECTRONIC MEDICAL RECORD; HEPATIC ARTERY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; METASTASIS; MIDDLE AGED; SURVIVAL; UVEA TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DRUG DELIVERY SYSTEMS; DRUG MONITORING; ELECTRONIC HEALTH RECORDS; FEMALE; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UVEAL NEOPLASMS; YOUNG ADULT;

EID: 84857765028     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.5.300     Document Type: Article

References (39)

1. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011;16(1):5-24.
2. Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. Semin Oncol 2010;37(2):127-138.
3. Schmittel A, Bechrakis NE, Martus P, Mutlu D, Scheibenbogen C, Bornfeld N et al. Independent prognostic factors for distant metastases and survival in patients with primary uveal melanoma. Eur J Cancer 2004;40(16):2389-2395.
4. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. Development of metastatic disease after enrollment in the COMs trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma study Group Report no. 26. Arch Ophthalmol 2005;123(12):1639-143.
5. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma study (COMs): COMs report no. 15. Arch Ophthalmol 2001;119(5):670-676.
6. Bakalian S, Marshall JC, Logan P, Faingold D, Maloney S, Di Cesare S, et al. Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res 2008;14(4):951-956.
7. Vahrmeijer AL, van de Velde CJ, Hartgrink HH, Tollenaar RA. Treatment of melanoma metastases confined to the liver and future perspectives. Dig surg 2008;25(6):467-472.
8. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991;98(3):383-389; discussion 90.
9. Eskelin S, Pyrhonen S, Hahka-Kemppinen M, Tuomaala S, Kivela T. A prognostic model and staging for metastatic uveal melanoma. Cancer 2003;97(2):465-475.
10. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma study Group Report 23. J Clin Oncol 2004;22(12):2438-2444.
11. Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB. Variates of survival in metastatic uveal melanoma. J Clin Oncol 2005;23(31):8076-8080.
12. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-723.
13. Ridolfi L, Ridolfi R. Anti-CTLA-4 therapy in melanoma: role of ipilimumab (MDx-010). Expert Rev Dermatol. [Review] 2009;4(3):199-210.
14. Augsburger JJ, Correa ZM, shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 2009;148(1):119-127.
15. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363(9):809-819.
16. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GnA11 in uveal melanoma. N Engl J Med 2010;363(23):2191-2199.
17. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341(27):2039-2048.
18. Lorenz M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000;18(2):243-254.
19. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995;76(9):1665-1670.
20. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase iii study. J Clin Oncol 2004;22(6):1118-1125.
21. Leyvraz S, Spataro V, Bauer J, Pampallona S, salmon R, Dorval T, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997;15(7):2589-2595.
22. Cantore M, Fiorentini G, Aitini E, Davitti B, Cavazzini G, Rabbi C, et al. Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver. Report of a phase ii study. Tumori 1994;80(1):37-39.
23. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
24. Rimoldi D, Salvi S, Lienard D, Lejeune FJ, Speiser D, Zografos L, et al. Lack of BRAF mutations in uveal melanoma. Cancer Res 2003;63(18):5712-5715.
25. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004;64(20):7205-7209.
26. Cree IA. Cell cycle and melanoma-two different tumours from the same cell type. J Pathol 2000;191(2):112-114.
27. Rivoire M, Kodjikian L, Baldo S, Kaemmerlen P, Négrier S, Grange JD. Treatmentof liver metastases from uveal melanoma. Ann surg Oncol 2005;12(6):422-428.
28. Pons F, Plana M, Caminal JM, Pera J, Fernandes I, Perez J, Garcia-Del-Muro X, et al. Metastatic uveal melanoma: is there a role for conventional chemotherapy? - A single center study based on 58 patients. Melanoma Res. 2011;21(3):217-222.
29. Becker JC, Terheyden P, Kampgen E, Wagner S, Neumann C, Schadendorf D, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 2002;87(8):840-845.
30. Alexander HR, Jr., Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2003;9(17):6343-6349.
31. Noter SL, Rothbarth J, Pijl ME, Keunen JE, Hartgrink HH, Tijl FG, et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res 2004;14(1):67-72.
32. Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006;17(4):578-583.
33. Siegel R, Hauschild A, Kettelhack C, Kahler KC, Bembenek A, Schlag PM. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Eur J surg Oncol 2007;33(5):627-632.
34. van Iersel LB, Hoekman EJ, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, et al. Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. Ann surg Oncol 2008;15(7):1891-1898.
35. Melichar B, Voboril Z, Lojik M, Krajina A. Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbazine. Hepatogastroenterology 2009;56(93):1157-1162.
36. Egerer G, Lehnert T, Max R, Naeher H, Keilholz U, Ho AD. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients. Int J Clin Oncol 2001;6(1):25-28.
37. Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol 2007;25(8):978-986.
38. Feun LG, Reddy KR, Scagnelli T, Yrizarry JM, Guerra JJ, Russell E, et al. A phase i study of chemoembolization with cisplatin, thiotepa, and lipiodol for primary and metastatic liver cancer. Am J Clin Oncol 1999;22(4):375-380.
39. Agarwala SS, Panikkar R, Kirkwood JM. Phase i/ii randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver. Melanoma Res 2004;14(3):217-222.